Clinical Trial Update: GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GDC-0084 in combination with trastuzumab for HER2-positive breast cancer with brain metastases has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• GDC-0084
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED